Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR18034 for Pain Management After Inguinal Hernia Repair
NCT04551924Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bupivacaine liposome in postoperative pain (5 arms), sponsored by Hengrui. Primary endpoint: Number of SAEs and treatment-related severe AEs at 14 days. Status: unknown.
02
Drugs
bupivacaine liposome
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04551924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551924.